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Xiaoyan Chang, Ying Jiang, Ji Li and Jie Chen*Abstract
Background: Intraductal tubular adenoma of the pancreas, pyloric gland type (ITA), is an infrequent intraductal
benign lesion located in the main duct and large branch duct of the pancreas. The purpose of this report is to
introduce seven new cases and to compare their clinicopathologic features and KRAS mutations to gastric-type
intraductal papillary mucinous neoplasms (IPMNs) and intraductal tubulopapillary neoplasms (ITPNs).
Methods: Clinical findings, morphologic features, immunophenotypes and KRAS alterations were investigated in 7
patients with intraductal tubular adenomas, 16 patients with gastric-type intraductal papillary mucinous neoplasms
and 6 patients with intraductal tubulopapillary neoplasms.
Results: There were more female patients in the ITA and gastric-type IPMN groups, whereas the opposite pattern
was observed in the ITPN group. ITAs and gastric-type IPMNs were lined by columnar cells, similar to pyloric glands,
with large extracellular deposits of mucin. ITPNs were polypoid and papillary mass located in the pancreatic ducts,
which did not show large deposits of mucin. All ITAs and gastric-type IPMNs expressed MUC5AC strongly and
diffusely, and 3/6 ITPNs expressed MUC5AC focally and weakly. KRAS mutations were identified in 4 ITAs (4/7, 57%),
9 IPMNs (9/16, 56%) and 2 ITPNs (2/6, 33%).
Conclusion: The intraductal tubular adenoma should not be considered a precursor lesion of intraductal
tubulopapillary neoplasms. No adequate data established ITA should separate as a specific entity from IPMNs.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_172
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Due to the application of advanced medical imaging,
more and more intraductal lesions of the pancreas are
being detected; however, their pathological classification
is more complex. The term of intraductal papillary mu-
cinous neoplasm (IPMN) has traditionally been used to* Correspondence: xhblk@163.com
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unless otherwise stated.describe them, and it is widely recognized. However,
some other parallel nomenclatures also exist. In the
2010 edited WHO classification of digestive diseases,
intraductal lesions of the pancreas were divided into two
types: IPMNs and a new entity termed intraductal tubu-
lopapillary neoplasms (ITPNs) [1].
In 1999, the term ‘pyloric gland adenoma’ was first put
forward by Bakotic B.W. as a name for a novel pancre-
atic intraductal lesion that was distinct from IPMN [2].
Subsequently, 17 cases have been documented inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The clinical presentations and pathological




Gender (M/F) 10/6 5/2 2/4
Age (average age) 39-78 (61) 47-74 (58) 48-70 (64)
Site (head/body/tail) 10/3/3 4/3/0 4/1/1
Clinical features
Symptoms※ 8/5/3 4/2/1 (back pain) 4/1/1 (jaundice)
Chronic pancreatitis 5/16 4/7 2/6











Diameter 1-6 cm 0.6-3 cm 1.5-4.5 cm









MUC5AC 16/16 7/7 3/6
MUC1 0/16 0/7 3/6
MUC2 9/16 (goblet cells) 3/7 (goblet cells) 0
Ki-67 index <1% 2/7 3-5% >20%
P53 - - 3/6
KRAS mutation 9/16 (56%) 4/7 (57%) 2/6 (33%)
※From left to right: abdominal discomfort/routine checkup/other symptoms,
such as jaundice, back pain, et al.
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‘intraductal tubular adenoma’ (pyloric gland-type; ITA).
ITAs showed some similarities with IPMNs and ITPNs
and also some obvious differences from them.
Besides the WHO classification of intraductal lesions,
another system classified intraductal tumors into IPMNs
and intraductal tubular neoplasms (ITNs) based on the
papillary or tubular structures [11,12]. ITNs were further
subclassified into ITAs and intraductal tubular carcinoma
(ITCs) depending on the degree of epithelial dysplasia. In
this classification, ITA was a precursor lesion to ITC [3,4].
ITC is regarded as a variant of ITPN according to the tubu-
lar architectures. Morphologically, ITAs were the benign
form and ITPNs were the malignant form. It is doubtful
that ITAs may be the precancerous lesion of ITPNs.
The purpose of this study was to report upon a further
7 cases of ITA and to delineate the clinicopathologic
characteristics, immunohistochemical features and KRAS
mutation rate in these ITAs compared with IPMNs
and ITPNs.
Methods
Patients and tissue samples
All selected cases were from Peking Union Medical College
Hospital (PUMCH) in 2001–2009 and re-examined by
other two senior pathologists. Sixteen cases of gastric-type
IPMNs, six cases of ITPNs and seven cases of ITAs were
selected. ITAs were diagnosed based on the following
definition: a localized polypoid mass within large duct
and characterized microscopically by close packing of
the tubular pyloric glands. Immunohistochemical staining
was performed using the enVision method. All ITA,
gastric-type IPMN and ITPN cases were stained for
MUC1 (Novocastra Laboratories Ltd., clone Ma695,
dilution 1:100), MUC2 (Novocastra Laboratories Ltd.,
clone Ccp58, dilution 1:100) and MUC5AC (Novocastra
Laboratories Ltd., clone CLH2, dilution 1:100). Ki-67
(Immunotech S.A., 1:200) and p53 (Novo, DO7, 1:200)
staining was also performed. This study was approved
by the Ethics Committee of the Peking Union Medical
College Hospital, and informed consent was obtained
from all cases.
DNA samples and mutation analyses
Paraffin-embedded tumor samples were microdissected
by hand. Genomic DNA was extracted using QIAmp
DNA Mini Kit (Qiagen, Germany). KRAS (exons 12, 13)
mutations were detected using two methods: real-time
PCR and traditional PCR amplification of genomic DNA
and direct sequencing of subsequent PCR products.
Real-time PCR was performed using ABI 7500 and
StepOne (Applied Biosystems, USA). The PCR reaction
mixture was generated based on standard assay procedures.
The thermal cycling was as follows: an initial heating stepat 95°C for 5 min, followed by 40 cycles of 95°C for
15 sec, 69°C for 10 sec, and 62°C for 60 sec (fluorescence
collection). Genomic DNA (40 ng per sample) was
amplified using primers covering the coding region. Prior
to sequencing, all PCR products were purified (QIAquick
PCR Purification Kit; Qiagen). Sequencing was performed
by Sangon Corp. (Beijing Sangon, China) using the ABI
PRISM 3730XL system (Applied Biosystems, USA). All
samples with a genetic alteration in the target gene were
subsequently sequenced in the reverse direction to con-
firm the mutation. Surrounding non-tumorous tissue or
matched normal tissue were served as the control.
Results
Clinical presentations
The major clinicopathologic features of ITAs, gastric-type
IPMNs and ITPNs are summarized in Table 1. More female
patients were present in the ITA and gastric-type IPMN
groups, whereas the opposite pattern was observed in the
ITPN group. The average age of patients was similar.
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Some patients found the pancreatic mass by routine
checkup. Some patients of the three groups had a his-
tory of chronic pancreatitis and diabetes mellitus.
CA19-9 and CEA were occasionally elevated. Compar-
ing with gastric-type IPMNs and ITPNs, the patients of
ITAs did not have specific clinical presentations. Com-
puted tomography and B ultrasound revealed pancre-
atic cystic masses, and the head of pancreas was the
most frequently involved site for all three lesions. The
common bile duct appeared normal.
Pathological findings
All seven ITAs were well demarcated, and polypoids were
located within the cystically dilated ducts (Figure 1A, D),
which comprised closely packed ducts or tubular glandsFigure 1 Pathological comparisons between intraductal tubular adenom
mucinous neoplasm (IPMN; B, E, H, K) and intraductal tubulopapillary n
nodular mass in the dilated pancreatic duct (A, C), whereas IPMN shows a
ITA and IPMN comprise closely packed ducts or tubular glands that are line
cytoplasm and basally oriented nuclei (D, E, G, H). ITPN shows tightly-pack
secreted mucin (F). The neoplastic cells show high-grade atypia with scant
IPMN express MUC5AC robustly and diffusely (J, K) and ITPN expresses MUthat resembled pyloric glands (Figure 1G). Gastric-type
IPMNs were papillary and mucin was located in the
main and branch ducts (Figure 1B, E). The glands were
lined with cuboidal to columnar mucin-secreting cells
with abundant cytoplasm and basally oriented nuclei
similar to ITAs (Figure 1H). Sporadic goblet cells were
observed in some ITAs and gastric-type IPMNs. Mild cell
atypia was observed with no obvious hyperchromatic nu-
clei. Mitotic figures were seldom occurred.
Grossly, ITPNs were located in the large pancreatic
ducts and showed polypoid nodules that obstructed the
duct (Figure 1C, F); a solid nodule was noted beside the
dilated duct in one case. Microscopically, ITPNs were
characterized by a tubulopapillary growth pattern with-
out secreted mucin and by back-to-back tubular glands
(Figure 1I). The neoplastic cells showed high-grade atypiaa (pyloric gland type; A,D,G,J), gastric-type intraductal papillary
eoplasm (ITPN; C, F, I, L). Grossly, ITA and ITPN show a polypoid and
papillary mass in the mucin-filled dilated duct (B). Microscopically,
d with cuboidal-to-columnar mucin-secreting cells with abundant
ed small glands with a tubulopapillary growth pattern without
cytoplasmic mucin. Intraductal necrotic foci are observed (I). ITA and
C1.
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were observed frequently.
Immunohistochemical findings
All the MUC expression is summarized in Table 1. ITAs
and gastric-type IPMNs expressed MUC5AC (Figure 1J, K)
but not MUC1 or MUC2, with negative P53 expression
and low proliferative index of ki-67. ITPNs were inclined to
expresse MUC1 (Figure 1L) and P53, but not MUC5AC
and MUC2, with a high proliferative index.
KRAS mutations
KRAS mutations were identified in 4 ITAs (4/7, 57%), 9
IPMNs (9/16, 56%) and 2 ITPNs (2/6, 33%). These muta-
tions all showed a single amino acid substitution in codon
12: Gly12Asp (GGT >GAT) or Gly12Val (GGT >GTT),
which are the most common mutational foci in pancreatic
carcinomas.
Discussion
IPMN is histopathologically subclassified into four sub-
types: gastric, intestinal, pancreatobiliary and oncocytic
[1]. The majority of gastric-type IPMNs are IPMNs with
low-grade dysplasia (IPMN adenoma). There are some
similarities that exist between gastric-type IPMNs and
ITAs. They are both located in the pancreatic ducts, pro-
ducing extracellular mucin and causing marked dilation
of the ducts. The lining epithelium comprises columnar
cells with morphologic, histochemical and immunohisto-
chemical features similar to those of gastric pylorus, im-
munoreactive to MUC5AC and negative to MUC1 and
MUC2. With regard to behavior, although very few
gastric-type IPMNs show high grade atypia or even inva-
sion, gastric-type IPMNs and ITAs are indolent lesions
and have a good prognosis.
Kato et al. [4] suggested that ITA was superimposed
upon gastric-type IPMN. In 2009, Runjan Chetty and
Stefano Serra [6] reviewed all ITA-associated literature
and divided ITA into two types, ITA without IPMN
(classic ITA or type A) or with gastric-type IPMN
(mixed ITA or type B). Fifty percent of the cases reported
in the literature may be classified as type A. Some experts
have suggested that type A ITA originated from a small
focus of gastric/pyloric metaplasia of the ductal cells and
that growed into the lumen with no radial extension. How-
ever, the classification of ITA had little clinical value. In
view of this, even if ITAs were diagnosed as gastric-type
IPMN, it would make no difference on clinical therapy.
ITPN is an additional intraductal lesion defined as an
intraductal tubule-forming epithelial neoplasm with high-
grade dysplasia and ductal differentiation without overt
production of mucin [1,13-15]. ITA shows some similar-
ities to ITPN in its histological growth pattern – a tubular
pattern with tightly packed small acinar glands. However,from the Table 1, we can see that ITAs were inclined to
present in aged men, immunoreactive to MUC5AC
and negative for MUC1, whereas ITPNs were inclined
to present in aged women,partially negative to MUC5AC
and positive for MUC1. The differences in patient popula-
tion and mucin expression indicate that ITAs and ITPNs
are distinct intraductal neoplasms of the pancreas.
Mutations in KRAS exon 2 (codons 12 and 13) are the
most frequently detected and earliest event in pancreatic
carcinogenesis. The presence of an activating KRAS
mutation has been noted in >90% of pancreatic ductal
adenocarcinomas (PDACs), and it is not specific for
pancreatic carcinoma. In some pre-neoplastic lesions
including pancreatic intraepithelial neoplasms (PanINs) and
IPMNs, KRAS mutations are detected frequently, increas-
ingly together with cell atypia [16]. In a review of the litera-
ture, two cases of ITA showed mutations in KRAS codon
12 [2,4]. In our study the ratio of KRAS mutations in ITAs
was unexpectedly high, up to 57%, a rate similar to gastric-
type IPMNs (56%) and much higher than that of ITPNs
(33%). In general, malignant lesions show higher rates of
mutation of this gene than precursor lesions, for example,
PanIN3 shows a much greater rate of KRAS mutation
than PanIN1. The rate of KRAS mutations does not
support the theory that ITAs are a precursor lesion of
ITPNs. Toru Furukawa has verified this conclusion atmole-
cular level [17].
Conclusions
Intraductal tubular adenoma (ITA) should not be a precur-
sor lesion of ITPN. Up to now, no adequate data established
ITA should separate as a specific entity from IPMNs.
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